Clinical trial
Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00007969 · QLT Inc., Industry · Completed
Key facts
| NCT number | NCT00007969 |
|---|---|
| Title | Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma |
| Official title | A Phase 1/2 Uncontrolled, Open Label Study Of Photodynamic Vaccination In Patients With Stage III/IV Malignant Melanoma |
| Lead sponsor | QLT Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | Detox-B adjuvant, verteporfin |
| Start date | Oct 1, 2000 |
| First posted | Mar 11, 2004 |
| Last update posted | Nov 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: